NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth
Novartis boosts long-term sales forecasts as blockbuster drugs like Kisqali and Scemblix drive strong momentum across its portfolio.
BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU
Bayer wins EU approval for Lynkuet, expanding its pharma portfolio with a hormone-free treatment for moderate to severe vasomotor symptoms ...
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth?
Cytokinetics' shares surge to a 52-week high as investor optimism grows over FDA approval prospects for aficamten.
Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus
Immunovant posts a wider Q2 loss as R&D spending rises, but progress on IMVT-1402 and batoclimab fuels its pipeline momentum.
Wall Street Analysts Believe Amicus Therapeutics ( FOLD ) Could Rally 76.32%: Here's is How to Trade
The consensus price target hints at a 76.3% upside potential for Amicus Therapeutics (FOLD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns
EVER, FOLD, LRCX and CBOE make the cut as top liquid stocks, with each boasting strong liquidity, growth attributes and operational efficiency.
Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y
CPRX Q3 earnings and revenues beat estimates, driven by strong Firdapse and Agamree sales, while raising the full-year 2025 total revenue guidance.
Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance
Viatris tops Q3 earnings and revenue estimates, lifts 2025 outlook, and expands its Japan presence with Aculys Pharma deal.
RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y
Recursion Pharmaceuticals narrows its Q3 loss but posts lower-than-expected revenues due to reduced collaboration revenues from its partners.
ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales
ADMA Biologics posts strong Q3 revenues and record Asceniv demand, but shares slip as higher taxes temper net income growth.
EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales
Exelixis posts strong Q3 results with earnings and revenue beats, boosted by Cabometyx sales, and narrows 2025 guidance.
Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y
RARE's Q3 loss widens and revenues miss estimates, despite year-over-year sales growth of key rare disease drugs.
Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up
MDGL's wider Q3 loss fails to deter investors, as soaring Rezdiffra sales drive revenues past estimates and lift the stock.
Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles
NVO's Q3 profit and revenues miss expectations as Wegovy and Ozempic growth slows amid U.S. compounding and pricing headwinds.
Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues
FOLD's third-quarter earnings top estimates as rising Galafold and Pombiliti + Opfolda sales lift revenues by 19% year over year.
ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down
Zoetis tops Q3 earnings forecasts but misses on revenues and trims 2025 sales outlook, sending shares lower on weak U.S. results.
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
XENE reports narrower-than-expected Q3 loss as the biotech advances multiple late-stage studies of azetukalner across epilepsy and mood disorders.
Amicus Therapeutics ( FOLD ) Beats Q3 Earnings and Revenue Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of +41.67% and +2.61%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates
APLS shares plunge 31% despite topping Q3 earnings and revenue estimates, as gains were driven by a one-time Sobi payment.
ALNY Q3 Earnings and Revenues Top Estimates on Higher Amvuttra Sales
Alnylam's Q3 earnings and revenues surge past forecasts, powered by booming Amvuttra sales and a key milestone payment from Roche.
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025
PRINCETON, N.J., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics ( Nasdaq: FOLD ) today announced that management will participate in upcoming presentations at the following investor conferences in November.
Amicus Therapeutics to Present at Upcoming Investor Conferences in November 2025 - Amicus Therapeutics ( NASDAQ:FOLD )
PRINCETON, N.J., Oct. 31, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics ( NASDAQ:FOLD ) today announced that management will participate in upcoming presentations at the following investor conferences in November.
BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales
Bausch Health's Q3 results top expectations as strong Salix and Solta sales fuel growth. Shares gain.
Amicus Therapeutics to Announce Third Quarter 2025 Financial Results on November 4, 2025 - Amicus Therapeutics ( NASDAQ:FOLD )
PRINCETON, N.J., Oct. 23, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics ( NASDAQ:FOLD ) today announced that the Company will host a conference call and live audio webcast on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss financial results for the quarter ended September 30, 2025.
FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months
Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
BAYRY's subsidiary BlueRock reports 36-month data showing its Parkinson's therapy bemdaneprocel remains safe and effective in easing motor symptoms.
All You Need to Know About Amicus Therapeutics ( FOLD ) Rating Upgrade to Strong Buy
Amicus Therapeutics (FOLD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SKYE Stock Plunges 60% as Obesity Candidate Misses Key Phase II Goal
Skye Bioscience stock nosedives 60% after its investigational obesity candidate, nimacimab, fails to meet the key goal in a mid-stage study.
Bet on These 3 Stocks With Upgraded Broker Ratings for Solid Returns
Broker upgrades fuel optimism for Amicus Therapeutics, Micron and General Dynamics as earnings outlook strengthens.
Can Galafold Drive Amicus' Growth Through the Rest of 2025?
Galafold's steady growth, rising sales and strong patent protection position Amicus for continued growth and momentum through 2025.
RIGL vs. FOLD: Which Biotech Stock Offers Better Growth Potential?
Rigel and Amicus are advancing rare disease therapies, with rising sales from key drugs fueling growth prospects in 2025.
Atara Biotherapeutics ( ATRA ) Soars 10.0%: Is Further Upside Left in the Stock?
Atara Biotherapeutics (ATRA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Strength Seen in Amicus Therapeutics ( FOLD ) : Can Its 6.4% Jump Turn into More Strength?
Amicus Therapeutics (FOLD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
This CSX Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday - Aveanna Healthcare Hldgs ( NASDAQ:AVAH ) , CSX ( NASDAQ:CSX )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. Needham analyst Gil Blum upgraded Amicus Therapeutics, Inc.
New 4-Year Data for Pombiliti® ( cipaglucosidase alfa-atga ) + Opfolda® ( miglustat ) Presented at ICIEM
Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of Pombiliti® + Opfolda® Long-Term Data Adds to the Growing Body of Evidence Supporting the Compelling Clinical Profile of ...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - Amicus Therapeutics ( NASDAQ:FOLD )
PRINCETON, N.J., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics FOLD today announced that management will participate in upcoming presentations at the following investor conferences in September. Cantor Global Healthcare Conference 2025 in New York, NY, on Wednesday, September 3, ...
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025
PRINCETON, N.J., Aug. 29, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics ( Nasdaq: FOLD ) today announced that management will participate in upcoming presentations at the following investor conferences in September.
Earnings Estimates Moving Higher for Amicus Therapeutics ( FOLD ) : Time to Buy?
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Does Amicus Therapeutics ( FOLD ) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Amicus ( FOLD ) Q2 Revenue Jumps 22%
Amicus Therapeutics ( NASDAQ:FOLD ) , a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP earnings. The company reported GAAP revenue of $154.7 million, up from $126.7 million ( GAAP ) a year ...
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Amicus Therapeutics ( FOLD ) Misses Q2 Earnings Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Amicus Therapeutics Announces Second Quarter 2025 Financial Results and Corporate Updates
Q2 2025 Total Revenue of $154.7M, up 18% at ...
Moderna ( MRNA ) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Moderna (MRNA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Amicus Therapeutics ( FOLD ) to Report a Decline in Earnings: What to Look Out for
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics Announces Approval of Pombiliti® ( cipaglucosidase alfa ) + Opfolda® ( miglustat ) in Japan - Amicus Therapeutics ( NASDAQ:FOLD )
PRINCETON, N.J., and TOKYO, June 25, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics FOLD today announced that Japan's Ministry of Health, Labour and Welfare ( MHLW ) has approved Pombiliti ( cipaglucosidase alfa ) + Opfolda ( miglustat ) for the treatment of adult patients with late-onset Pompe ...
New Strong Sell Stocks for June 3rd
FOLD, BRCC and VLVLY have been added to the Zacks Rank #5 (Strong Sell) List on May 3, 2025.
New Analysis of Pombiliti® ( cipaglucosidase alfa-atga ) + Opfolda® ( miglustat ) Published in Muscle and Nerve
PRINCETON, N.J., June 03, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics ( Nasdaq: FOLD ) , today announced the publication of a post-hoc analysis of data from the ERT-experienced cohort of the PROPEL study of cipaglucosidase alfa-atga + miglustat ( cipa+mig ) in adults with late-onset Pompe ...
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - Amicus Therapeutics ( NASDAQ:FOLD )
PRINCETON, N.J., May 30, 2025 ( GLOBE NEWSWIRE ) -- Amicus Therapeutics FOLD today announced that management will participate in upcoming presentations at the following investor conferences in June. Jefferies Global Healthcare Conference 2025 in New York, NY, on Wednesday, June 4, 2025, at ...
